Evidence map›Paper›PMID 37418141›Full record

ReviewInternational journal of clinical oncology2023

Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.

Kenji Ishikura, Kenji Omae, Sho Sasaki, Yugo Shibagaki, Satoko Ichioka, Yusuke Okuda, Kenichiro Koitabashi, Koichi Suyama, Takuro Mizukami, Chihiro Kondoh and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kenji Ishikura *Department of Pediatrics, Kitasato University School of Medicine, Kawasaki, Japan.
Kenji Omae *Department of Innovative Research and Education for Clinicians and Trainees, Fukushima Medical University Hospital, Fukushima, Japan.
Sho Sasaki *Section of Education for Clinical Research, Kyoto University Hospital, Kyoto, Japan.
Yugo ShibagakiDivision of Nephrology and Hypertension, Department of Internal Medicine, Saint Marianna University School of Medicine, Kanagawa, Japan. shibagaki@marianna-u.ac.jp.
Satoko IchiokaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan.
Yusuke OkudaDepartment of Pediatrics, Kitasato University School of Medicine, Kawasaki, Japan.
Kenichiro KoitabashiDivision of Nephrology, Inagi Municipal Hospital, Tokyo, Japan.
Koichi SuyamaDepartment of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Takuro MizukamiDepartment of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
Chihiro KondohDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Sumio HirataDepartment of Academic Education, I & H Co., Ltd, Ashiya, Japan.
Takeshi MatsubaraDepartment of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0002-2380-1551
Junichi HoshinoDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Motoko YanagitaDepartment of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible.

Indexed as

Antineoplastic AgentsCancer SurvivorsNeoplasmsRenal Insufficiency, ChronicHumansPractice Guidelines as TopicAntineoplastic AgentsCancer survivorsChronic kidney diseaseEpidemiologyRenal replacement therapyTreatment

Identifiers

PMID37418141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.